

Laurus Labs Limited
Corporate Office
2nd Floor, Serene Chambers, Road No. 7
Banjara Hills, Hyderabad - 500034, Telangana, India
T +91 40 39804333 / 2342 0500 / 501
F +91 40 3980 4320



January 29, 2018

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	---

Dear Sirs,


Sub: Press Release

Please find herewith the Press Release of the Results of the Quarter and Nine Months period ended December 31, 2017.

Please take the information on record.

Thanking you,

Yours sincerely,
For Laurus Labs Limited


G. Venkateswar Reddy
Company Secretary



LAURUS LABS DELIVERS IMPROVED RESULTS FOR 9M FY18

9M FY18 Revenues up 4.5%

9M FY18 EBITDA grows 1.7%

9M FY18 PBT grows 12.1%

9M FY18 PAT grows 3.0%

Hyderabad, January 29, 2018: Laurus Labs Ltd. (Laurus BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010), a leading research and development driven pharmaceutical company in India announces its Q3 & 9M FY18 results.

Q3 FY18 Laurus reported:

- Total net revenue stood at Rs. 4,789 mn
- EBITDA stood at Rs. 972 mn, margins at 20.3%
- PBT at Rs.486 mn, margin of 10.1%
- PAT at Rs. 349 mn, margins at 7.3%
- EPS (Diluted) for the period at Rs. 3.3 per share (not annualised)

Commenting on the results announcement, Dr. Satyanarayana Chava - CEO said;

"During the quarter, we have displayed enhanced performance in our Synthesis division, led by commencement in supplies from Unit 5 to Aspen. Generic API portfolio reported a marginal decline in growth due to lower contribution from Hep C, but Oncology and Other APIs showing a robust growth. Overall an expanding product portfolio and unrelenting focus on cost efficiencies have led to better margins. I am confident that we will continue to maintain our leadership position in ARV API's, as we see plenty of growth opportunities on offer in developed markets and with introduction of second line therapies. The Synthesis and FDF businesses will see full potential in the coming years as we expect to ramp up operations with our recent investments. We have received EIR from USFDA for Units 1&3 reflecting our commitment to Quality".

Commenting on the results announcement, V V Ravi Kumar, ED & Chief Financial Officer said;

"On 9M FY 18 basis our revenues grew by 4.5%. EBIDTA margins came in at 21.4% benefiting from better product mix due to higher supplies from Synthesis business, and also owing to improved

JANUARY 29, 2018

Press Release



efficiencies. PBT growth of 12.1% during the 9M period. PAT came in at INR 1,225mn for 9M FY 18, overall tax rate has increased as against 9M FY 17. We have recently concluded several expansion initiatives which will aid growth in Generic FDF and Synthesis. This will be well supported by sustainable performance in API's and Ingredients businesses. Going ahead, we aim to leverage our existing investments and further strengthen our balance sheet."

Business Highlights:

Overall

- Total revenues grew by 4.5 % in 9M FY18.
- R & D spent of INR 754 million and 5.1 % as percentage of sales during 9M FY18.
- Unit IV Inaugurated in the month of November 2017 the facility will add to the capacities for Synthesis & Ingredients business
- API Unit located at Achutapuram Visakhapatnam, of Sriam Labs Pvt. Ltd. A wholly owned subsidiary of the Company acquired on a slump sale basis. UNIT 6

Generic API

- Successfully completed USFDA inspection for API facility in Unit 2 without any 483 observations. Received EIR for the same
- Successfully completed the USFDA inspection for Unit 1&3. Received EIR for the same in the month of November 2017.
- WHO inspection for unit 1&3 was successfully Audited & Approved, received Inspection Assessment Report.
- The Company has filed 219 patent applications and 50 patent granted as on 31 Dec 2017.

Generic FDF

- Filed 8 ANDAs with USFDA, one dossier in Canada, two dossiers in Europe, one dossier with WHO and one dossier in South Africa. Completed 20 products validations.
- FDF Opex of INR 723 mn which includes INR 231 mn related to the R&D during 9MFY18.
- USFDA inspection scheduled in Feb 2018 for Unit 2.
- Current manufacturing capacity of Unit 2 is at 5 billion units.
- Tenofovir (TDF) will be launched based on the final approval from USFDA.

Synthesis

- Validations of 4 Products completed.
- Set up a dedicated block in Unit 4 for global partner, C2 Pharma.
- Commenced commercial supplies from Unit 5 to Aspen.

General

- Laurus Labs is certified as "Best Place to Work" in Jan 2018.

JANUARY 29, 2018

Press Release



- Laurus Labs entered the Fortune 500 list of companies in India.
- Received Indian Innovation Award from Clarivate Analytics.

-ENDS-

About Laurus Labs Limited

Laurus is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Initiatives are in place to develop Finished Dosages Forms capabilities on the back of existing strengths in APIs. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses. **Corporate Identification No: L24239AP2005PLC047518**

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

Pavan Kumar N
Laurus Labs Ltd.
Tel: +91 40 3980
4380/+919246564666/7337353848
Email: mediarelations@lauruslabs.com



DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

JANUARY 29, 2018

Press Release